Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01169753 · ClinicalTrials.gov registry record · NA
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01169753: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT01169753 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01169753, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if Nuvigil (armodafinil) can help to control fatigue in patients with CML. The safety of this drug will also be studied.
Interventions
- DRUG Placebo
- DRUG Armodafinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01169753
The ClinicalTrials.gov registry entry for NCT01169753 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01169753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01169753 about?
NCT01169753 is a clinical study titled "Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients". The goal of this clinical research study is to learn if Nuvigil (armodafinil) can help to control fatigue in patients with CML. The safety of this drug will also be studied.
What is the current status of trial NCT01169753?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2011-05. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01169753?
The interventions under investigation include: Placebo (DRUG), Armodafinil (DRUG).
Who is sponsoring clinical trial NCT01169753?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.